Bad prospects for cancer

Jens Junker has been Managing Director of Rotop Pharmaka GmbH in Dresden since 2014. Previously, the Saxon spent 20 years as Managing Director for various mechanical engineering companies in the Czech Republic, Poland, China and the USA. Photo: Arvid Müller

The Dresden-based company Rotop Pharmaka is a prime example of the boom in radiopharmaceuticals. Rotop, which emerged from the former Central Institute for Nuclear Research, is now one of the world's leading manufacturers of radioactive pharmaceuticals for diagnostics and cancer therapy. Managing Director Jens Junker leads a rapidly growing team of over 200 employees and is planning to build two new production facilities for therapeutics - a unique project in Europe. With the support of investors such as Genui, SHS and the WMS Growth Fund Saxony, the company aims to significantly expand its capacities and produce over 100,000 patient doses per year in the long term.

Read the full article by Michael Rothe in Die Wirtschaft in Sachsen from October 1, 2025.